NEW YORK – Opgen subsidiary Curetis announced Tuesday it is collaborating with Sweden's Karolinska Institute to identify bacterial co-infections in patients with COVID-19 pneumonia.
Curetis provided the institute, which has previously evaluated the Unyvero system and Hospitalized Pneumonia panel, with additional Unyvero analyzers and HPN cartridges to increase throughput. COVID-19 patients in intensive care units and on ventilation are at a higher risk of developing deadly bacterial co-infections, Curetis said.